Approvals & regulatory · first seen 14h ago, updated 14h ago
Glytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and Infants
The designation covers hospitalized newborns and infants from birth to less than 2 years of age, a population for which no insulin dosing recommendation software has been FDA-cleared. ATLANTA, Sept. 24, 2026 /PRNewswire/ -- Glytec, the heal…
Summary from PR Newswire - FDA Approval.